^
Association details:
| Biomarker: | STK11 mutation |
|---|---|
| Cancer: | Solid Tumor |
| Drug Class: | Immunotherapy |
| Direction: | Resistant |
Evidence:
Source:
Title:
Biomarker development 40P - Interplay between Mutational Profile and TMB on overall survival: A Posthoc Analysis of 1,662 Metastatic Patients Treated with Immune Checkpoint Inhibitors.
Published date:
12/02/2021
Excerpt:
From that same TMB cutoff, a Cox multivariate analysis stratified by median TMB revealed that mutations in STK11 (HR 2.95; p<0.0007) and TP53 (HR 1.89; p<0.0032) were associated with a higher risk of death. Otherwise, mutations in TERT (HR 0.54; p<0.0044) and NOTCH3 (HR 0.23; p<0.0355) were protective.... the mutational profile can contribute to define outcomes to ICIs.
